Search

Your search keyword '"Ali, Haris"' showing total 754 results
Start Over Author "Ali, Haris"
754 results on '"Ali, Haris"'

1. Comparing transplant outcomes in ALL patients after myeloablative conditioning in mismatch-related or unrelated donor settings

Author

Otoukesh, Salman, Yang, Dongyun, Mokhtari, Sally, Pourhassan, Hoda, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Sandhu, Karamjeet, Aribi, Ahmed, Artz, Andrew, Aldoss, Ibrahim, Pullarkat, Vinod, Ali, Haris, Blackmon, Amanda, Becker, Pamela, Curtin, Peter, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

2. State-transition modeling of blood transcriptome predicts disease evolution and treatment response in chronic myeloid leukemia

Author

Frankhouser, David E, Rockne, Russell C, Uechi, Lisa, Zhao, Dandan, Branciamore, Sergio, O’Meally, Denis, Irizarry, Jihyun, Ghoda, Lucy, Ali, Haris, Trent, Jeffery M, Forman, Stephen, Fu, Yu-Hsuan, Kuo, Ya-Huei, Zhang, Bin, and Marcucci, Guido

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Genetics, Rare Diseases, Clinical Research, Cancer, Hematology, Detection, screening and diagnosis, 4.1 Discovery and preclinical testing of markers and technologies, Mice, Animals, Transcriptome, Fusion Proteins, bcr-abl, Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Tetracyclines, Drug Resistance, Neoplasm, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Chronic myeloid leukemia (CML) is initiated and maintained by BCR::ABL which is clinically targeted using tyrosine kinase inhibitors (TKIs). TKIs can induce long-term remission but are also not curative. Thus, CML is an ideal system to test our hypothesis that transcriptome-based state-transition models accurately predict cancer evolution and treatment response. We collected time-sequential blood samples from tetracycline-off (Tet-Off) BCR::ABL-inducible transgenic mice and wild-type controls. From the transcriptome, we constructed a CML state-space and a three-well leukemogenic potential landscape. The potential's stable critical points defined observable disease states. Early states were characterized by anti-CML genes opposing leukemia; late states were characterized by pro-CML genes. Genes with expression patterns shaped similarly to the potential landscape were identified as drivers of disease transition. Re-introduction of tetracycline to silence the BCR::ABL gene returned diseased mice transcriptomes to a near healthy state, without reaching it, suggesting parts of the transition are irreversible. TKI only reverted the transcriptome to an intermediate disease state, without approaching a state of health; disease relapse occurred soon after treatment. Using only the earliest time-point as initial conditions, our state-transition models accurately predicted both disease progression and treatment response, supporting this as a potentially valuable approach to time clinical intervention, before phenotypic changes become detectable.

Published
2024

3. Phase 2 study of add-on parsaclisib for patients with myelofibrosis and suboptimal response to ruxolitinib: final results.

Author

Yacoub, Abdulraheem, Borate, Uma, Rampal, Raajit, Ali, Haris, Wang, Eunice, Gerds, Aaron, Hobbs, Gabriela, Kremyanskaya, Marina, Winton, Elliott, OConnell, Casey, Goel, Swati, Oh, Stephen, Schiller, Gary, McCloskey, James, Palmer, Jeanne, Holmes, Houston, Hager, Steven, Assad, Albert, Erickson-Viitanen, Susan, Zhou, Feng, and Daver, Naval

Subjects
Humans, Primary Myelofibrosis, Phosphatidylinositol 3-Kinases, Pyrazoles, Nitriles, Pyrimidines, Pyrrolidines
Abstract

Ruxolitinib reduces spleen volume, improves symptoms, and increases survival in patients with intermediate- or high-risk myelofibrosis. However, suboptimal response may occur, potentially because of signaling via the phosphoinositide 3-kinase (PI3K)/protein kinase B pathway. This phase 2 study evaluated dosing, efficacy, and safety of add-on PI3Kδ inhibitor parsaclisib for patients with primary or secondary myelofibrosis with suboptimal response to ruxolitinib. Eligible patients remained on a stable ruxolitinib dose and received add-on parsaclisib 10 or 20 mg, once daily for 8 weeks, and once weekly thereafter (daily-to-weekly dosing; n = 32); or parsaclisib 5 or 20 mg, once daily for 8 weeks, then 5 mg once daily thereafter (all-daily dosing; n = 42). Proportion of patients achieving a ≥10% decrease in spleen volume at 12 weeks was 28% for daily-to-weekly dosing and 59.5% for all-daily dosing. Proportions of patients achieving ≥50% decrease at week 12 in Myelofibrosis Symptom Assessment Form and Myeloproliferative Neoplasms Symptom Assessment Form symptom scores were 14% and 18% for daily-to-weekly dosing, and 28% and 32% for all-daily dosing, respectively. Most common nonhematologic treatment-emergent adverse events were nausea (23%), diarrhea (22%), abdominal pain and fatigue (each 19%), and cough and dyspnea (each 18%). New-onset grade 3 and 4 thrombocytopenia were observed in 19% of patients, each dosed daily-to-weekly, and in 26% and 7% of patients dosed all-daily, respectively, managed with dose interruptions. Hemoglobin levels remained steady. The addition of parsaclisib to stable-dose ruxolitinib can reduce splenomegaly and improve symptoms, with manageable toxicity in patients with myelofibrosis with suboptimal response to ruxolitinib. This trial was registered at www.clinicaltrials.gov as #NCT02718300.

Published
2024

6. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

Author

Desai, Amrita, Samara, Yazeed, Yang, Dongyun, Ball, Brian, Braun, Adam, Koller, Paul, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Arslan, Shukaib, Otoukesh, Salman, Sandhu, Karamjeet, Aldoss, Ibrahim, Ali, Haris, Salhotra, Amandeep, Al Malki, Monzr M., Artz, Andrew, Becker, Pamela, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Curtin, Peter, Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

7. Anti-CD3/CD7 immunoconjugate (T-Guard) for severe, steroid-refractory GVHD: final report of BMT CTN 2002

Author

Meyers, Gabrielle, Hamadani, Mehdi, Martens, Michael, Ali, Haris, Chevallier, Patrice, Choe, Hannah, Harris, Andrew C., Holler, Ernst, van Hooren, Eric, Klaassen, Willem, Leifer, Eric, van Oosterhout, Ypke, Perez, Lia, Pusic, Iskra, Stelljes, Matthias, van der Velden, Walter, Ammatuna, Emanuele, Beauvais, David, Cornillon, Jérôme, Maziarz, Richard T., Schetelig, Johannes, Romeril, Jennifer, MacMillan, Margaret L., Levine, John E., and Socié, Gérard

Published
2023
Full Text
View/download PDF

10. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis

Author

Tamari, Roni, McLornan, Donal P., Ahn, Kwang Woo, Estrada-Merly, Noel, Hernández-Boluda, Juan Carlos, Giralt, Sergio, Palmer, Jeanne, Gale, Robert Peter, DeFilipp, Zachariah, Marks, David I., van der Poel, Marjolein, Verdonck, Leo F., Battiwalla, Minoo, Diaz, Miguel Angel, Gupta, Vikas, Ali, Haris, Litzow, Mark Robert, Lazarus, Hillard M., Gergis, Usama, Bashey, Asad, Liesveld, Jane, Hashmi, Shahrukh, Pu, Jeffrey J., Beitinjaneh, Amer, Bredeson, Christopher, Rizzieri, David, Savani, Bipin N., Abid, Muhammad Bilal, Ganguly, Siddhartha, Agrawal, Vaibhav, Ulrike Bacher, Vera, Wirk, Baldeep, Jain, Tania, Cutler, Corey, Aljurf, Mahmoud, Kindwall-Keller, Tamila, Kharfan-Dabaja, Mohamed A., Hildebrandt, Gerhard C., Pawarode, Attaphol, Solh, Melhem M., Yared, Jean A., Grunwald, Michael R., Nathan, Sunita, Nishihori, Taiga, Seo, Sachiko, Scott, Bart L., Nakamura, Ryotaro, Oran, Betul, Czerw, Tomasz, Yakoub-Agha, Ibrahim, and Saber, Wael

Published
2023
Full Text
View/download PDF

11. A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease

Author

Schroeder, Mark A, Khoury, H Jean, Jagasia, Madan, Ali, Haris, Schiller, Gary J, Staser, Karl, Choi, Jaebok, Gehrs, Leah, Arbushites, Michael C, Yan, Ying, Langmuir, Peter, Srinivas, Nithya, Pratta, Michael, Perales, Miguel-Angel, Chen, Yi-Bin, Meyers, Gabrielle, and DiPersio, John F

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Sciences, Stem Cell Research - Nonembryonic - Human, Hematology, Clinical Trials and Supportive Activities, Stem Cell Research, Rare Diseases, Orphan Drug, Clinical Research, Transplantation, 6.1 Pharmaceuticals, 6.2 Cellular and gene therapies, Evaluation of treatments and therapeutic interventions, Adolescent, Adrenal Cortex Hormones, Adult, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Humans, Janus Kinase 1, Protein Kinase Inhibitors, Steroids, Cardiovascular medicine and haematology
Abstract

Acute graft-versus-host disease (aGVHD) following allogeneic hematopoietic cell transplantation (HCT) is a primary cause of nonrelapse mortality and a major barrier to successful transplant outcomes. Itacitinib is a Janus kinase (JAK)1-selective inhibitor that has demonstrated efficacy in preclinical models of aGVHD. We report results from the first registered study of a JAK inhibitor in patients with aGVHD. This was an open-label phase 1 study enrolling patients aged ≥18 years with first HCT from any source who developed grade IIB to IVD aGVHD. Patients with steroid-naive or steroid-refractory aGVHD were randomized 1:1 to itacitinib 200 mg or 300 mg once daily plus corticosteroids. The primary endpoint was safety and tolerability; day 28 overall response rate (ORR) was the main secondary endpoint. Twenty-nine patients (200 mg, n = 14; 300 mg, n = 15) received ≥1 dose of itacitinib and were included in safety and efficacy assessments. One dose-limiting toxicity was reported (grade 3 thrombocytopenia attributed to GVHD progression in a patient receiving 300 mg itacitinib with preexisting thrombocytopenia). The most common nonhematologic treatment-emergent adverse event was diarrhea (48.3%, n = 14); anemia occurred in 11 patients (38%). ORR on day 28 for all patients in the 200-mg and 300-mg groups was 78.6% and 66.7%, respectively. Day 28 ORR was 75.0% for patients with treatment-naive aGVHD and 70.6% in those with steroid-refractory aGVHD. All patients receiving itacitinib decreased corticosteroid use over time. In summary, itacitinib was well tolerated and demonstrated encouraging efficacy in patients with steroid-naive or steroid-refractory aGVHD, warranting continued clinical investigations. This trial was registered at www.clinicaltrials.gov as #NCT02614612.

Published
2020

13. Total Body Irradiation and Fludarabine with Post-Transplantation Cyclophosphamide for Mismatched Related or Unrelated Donor Hematopoietic Cell Transplantation

Author

Arslan, Shukaib, Desai, Amrita, Yang, Dongyun, Mokhtari, Sally, Tiemann, Katrin, Otoukesh, Salman, Samara, Yazeed, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Aribi, Ahmed, Becker, Pamela, Curtin, Peter, Artz, Andrew, Aldoss, Ibrahim, Ali, Haris, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

14. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Author

Aldoss, Ibrahim, Shan, Haoyue, Yang, Dongyun, Clark, Mary C., Al Malki, Monzr, Aribi, Ahmed, Agrawal, Vaibhav, Sandhu, Karamjeet, Salhotra, Amandeep, Pourhassan, Hoda, Koller, Paul, Ali, Haris, Artz, Andrew, Karras, Nicole, Pawlowska, Anna B., Murphy, Lindsey, Palmer, Joycelynne, Stein, Anthony, Marcucci, Guido, Pullarkat, Vinod, Nakamura, Ryotaro, and Forman, Stephen J.

Published
2024
Full Text
View/download PDF

15. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Author

Aldoss, Ibrahim, Yang, Dongyun, Tomasian, Vanina, Mokhtari, Sally, Jackson, Ryan, Gu, Zhaohui, Telatar, Milhan, Yew, Hooi, Al Malki, Monzr M., Salhotra, Amandeep, Khaled, Samer, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Mei, Matthew, Arslan, Shukaib, Koller, Paul, Artz, Andrew, Aoun, Patricia, Gu, Dongqing, Snyder, David, Stewart, Forrest M., Curtin, Peter, Stein, Anthony S., Pillai, Raju, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Nakamura, Ryotaro, and Afkhami, Michelle

Published
2022
Full Text
View/download PDF

18. Pacritinib and concurrent azole antifungal therapy is deliverable in patients with hematologic malignancies.

Author

Trang, Dina, Ngo, Dat, Ali, Haris, and Tinajero, Jose

Subjects
ANTIFUNGAL agents, HETEROCYCLIC compounds, HEMATOLOGIC malignancies, JANUS kinases, ELECTRONIC health records, DRUG interactions, NEUROTRANSMITTER uptake inhibitors, MYELOFIBROSIS, ADULTS
Abstract

Objective: Pacritinib is a novel kinase inhibitor approved for the treatment of adults with intermediate or high-risk primary or secondary myelofibrosis. Strong and moderate CYP3A4 inhibitors, such as some azole antifungals, are contraindicated or recommended to be avoided in combination with pacritinib, respectively. We aim to report our experience in patients who received pacritinib with concurrent azole antifungal therapy. Data Sources: We queried for patients with hematologic malignancies in the electronic medical record who received concurrent pacritinib and azole antifungal therapy. Data Summary: There were five cases of concurrent pacritinib and azole antifungal therapy in which none of the patients experienced grade 3 or higher non-hematologic toxicities. Some patients required dose modifications and/or interruptions in pacritinib therapy. Conclusion: This is the first clinical experience describing concurrent pacritinib and azole antifungals. Our experience shows that in the setting where this interaction cannot be avoided, concurrent administration is feasible with close monitoring and possible empiric dose reductions in select patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

20. Peritransplantation ruxolitinib administration is safe and effective in patients with myelofibrosis: a pilot open-label study

Author

Ali, Haris, Tsai, Ni-Chun, Synold, Timothy, Mokhtari, Sally, Tsia, Weimin, Palmer, Joycelynne, Stiller, Tracey, Al Malki, Monzr, Aldoss, Ibrahim, Salhotra, Amandeep, Rahmanuddin, Syed, Pullarkat, Vinod, Cai, Ji-Lian, Stein, Anthony, Forman, Stephen J., Marcucci, Guido, Mei, Matthew, Snyder, David S., and Nakamura, Ryotaro

Published
2022
Full Text
View/download PDF

23. Impact of spleen volume on post-allogenic hematopoietic transplant outcomes in myelofibrosis: Utility of 3D volumetrics in splenomegaly.

Author

Haseeb, Rafay, primary, Yang, Dongyun, additional, Motarjem, Pejman, additional, Al Malki, Monzr M., additional, Aldoss, Ibrahim, additional, Amanam, Idoroenyi Usua, additional, Otoukesh, Salman, additional, Forman, Stephen J., additional, Marcucci, Guido, additional, Rahmanuddin, Syed, additional, and Ali, Haris, additional

Published
2024
Full Text
View/download PDF

24. NCCN Guidelines® Insights: Systemic Mastocytosis, Version 3.2024

Author

Gotlib, Jason, primary, Gerds, Aaron T., additional, Abdelmessieh, Peter, additional, Ali, Haris, additional, Castells, Mariana, additional, Dunbar, Andrew, additional, Fein Revell, Ruth, additional, George, Tracy I., additional, Green, Steven, additional, Gundabolu, Krishna, additional, Hexner, Elizabeth, additional, Jain, Tania, additional, Jamieson, Catriona, additional, Kaesberg, Paul R., additional, Kuykendall, Andrew T., additional, Madanat, Yazan, additional, Manchanda, Naveen, additional, Masarova, Lucia, additional, May, Jori, additional, McMahon, Brandon, additional, Mohan, Sanjay R., additional, Nadiminti, Kalyan V., additional, Oh, Stephen, additional, Palmer, Jeanne, additional, Patel, Ami, additional, Patel, Anand A., additional, Podoltsev, Nikolai, additional, Rein, Lindsay, additional, Salit, Rachel, additional, Talpaz, Moshe, additional, Wadleigh, Martha, additional, Wall, Sarah, additional, Bergman, Mary Anne, additional, and Hochstetler, Cindy, additional

Published
2024
Full Text
View/download PDF

25. Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Author

Othman, Tamer, primary, Koller, Paul, additional, Pourhassan, Hoda, additional, Agrawal, Vaibhav, additional, Ngo, Dat, additional, Tinajero, Jose, additional, Ali, Haris, additional, Cai, Ji‐Lian, additional, Mei, Matthew, additional, Aribi, Ahmed, additional, Stein, Anthony S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Aldoss, Ibrahim, additional

Published
2024
Full Text
View/download PDF

28. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide

Author

Elmariah, Hany, Otoukesh, Salman, Kumar, Ambuj, Ali, Haris, Arslan, Shukaib, Shouse, Geoffrey, Pourhassan, Hoda, Nishihori, Taiga, Faramand, Rawan, Mishra, Asmita, Khimani, Farhad, Fernandez, Hugo, Lazaryan, Aleksandr, Nieder, Michael, Perez, Lia, Liu, Hien, Nakamura, Ryotaro, Pidala, Joseph, Marcucci, Guido, Forman, Stephen J., Anasetti, Claudio, Locke, Frederick, Bejanyan, Nelli, and Al Malki, Monzr M.

Published
2024
Full Text
View/download PDF

29. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

Author

Mac, Stephanie, Ngo, Dat, Yang, Dongyun, Chen, Jason, Ali, Haris, Arslan, Shukaib, Dadwal, Sanjeet, Salhotra, Amandeep, Cao, Thai, Karras, Nicole, Aldoss, Ibrahim, Koller, Paul, Artz, Andrew, Aribi, Ahmed, Sandhu, Karamjeet, Pullarkat, Vinod, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2021
Full Text
View/download PDF

31. Hypomethylating Agents are Effective in Treatment for Relapsed Myelofibrosis After Allogeneic Hematopoietic Cell Transplantation

Author

Ngo, Dat, Tinajero, Jose, Ladha, Abdullah, Malki, Monzr M. Al, Otoukesh, Salman, Amanam, Idoroenyi, and Ali, Haris

Abstract

•Myelofibrosis is a myeloproliferative neoplasm with a relapse rate of 10% to 30% after allogeneic transplantation (hematopoietic cell transplant [HCT]).•Hypomethylating agents have shown efficacy as salvage therapy by inducing an immune response and improving donor chimerism for myeloid neoplasm post-HCT.•Retrospective analysis of 12 myelofibrosis patients who relapsed post-HCT demonstrated 58% restoration of donor chimerism after 2 cycles and 50% molecular clearance of pre-HCT mutations.

Published
2024
Full Text
View/download PDF

32. Lower Weight-Based Mycophenolate Mofetil Dosing is Associated with Superior Outcomes after Haploidentical Hematopoietic Cell Transplant with Post-transplant Cyclophosphamide

Author

Elmariah, Hany, Otoukesh, Salman, Kumar, Ambuj, Ali, Haris, Arslan, Shukaib, Dimaggio, Elizabeth, Gonzalez, Rebecca, Shouse, Geoffrey, Pourhassan, Hoda, Nishihori, Taiga, Faramand, Rawan, Mishra, Asmita, Khimani, Farhad, Fernandez, Hugo, Lazaryan, Aleksandr, Nieder, Michael, Perez, Lia, Liu, Hien, Nakamura, Ryotaro, Pidala, Joseph, Marcucci, Guido, Forman, Stephen J, Anasetti, Claudio, Bejanyan, Nelli, and Malki, Monzr M Al

Abstract

•MMF is commonly included with haploidentical transplant with PTCy.•Dosing of MMF with this platform is not well studied.•In this study, lower MMF dose/kg was associated with improved relapse and PFS.•MMF dose/kg was not associated with risks of graft failure or graft-versus-host disease.•For haploidentical transplant with PTCy, lower dosing of MMF may improve outcomes.

Published
2024
Full Text
View/download PDF

34. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.

Author

Fei, Fei, Jariwala, Amar, Pullarkat, Sheeja, Loo, Eric, Liu, Yan, Tizro, Parastou, Ali, Haris, Otoukesh, Salman, Amanam, Idoroenyi, Artz, Andrew, Ally, Feras, Telatar, Milhan, Nakamura, Ryotaro, Marcucci, Guido, and Afkhami, Michelle

Subjects
MYELOPROLIFERATIVE neoplasms, CHRONIC myeloid leukemia, CHRONIC leukemia, MYELODYSPLASTIC syndromes, PROGNOSIS
Abstract

The accurate diagnosis and classification of myelodysplastic/myeloproliferative neoplasm (MDS/MPN) are challenging due to the overlapping pathological and molecular features of myelodysplastic syndrome (MDS) and myeloproliferative neoplasm (MPN). We investigated the genomic landscape in different MDS/MPN subtypes, including chronic myelomonocytic leukemia (CMML; n = 97), atypical chronic myeloid leukemia (aCML; n = 8), MDS/MPN-unclassified (MDS/MPN-U; n = 44), and MDS/MPN with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T; n = 12). Our study indicated that MDS/MPN is characterized by mutations commonly identified in myeloid neoplasms, with TET2 (52%) being the most frequently mutated gene, followed by ASXL1 (38.7%), SRSF2 (34.7%), and JAK2 (19.7%), among others. However, the distribution of recurrent mutations differs across the MDS/MPN subtypes. We confirmed that specific gene combinations correlate with specific MDS/MPN subtypes (e.g., TET2/SRSF2 in CMML, ASXL1/SETBP1 in aCML, and SF3B1/JAK2 in MDS/MPN-RS-T), with MDS/MPN-U being the most heterogeneous. Furthermore, we found that older age (≥65 years) and mutations in RUNX1 and TP53 were associated with poorer clinical outcomes in CMML (p < 0.05) by multivariate analysis. In MDS/MPN-U, CBL mutations (p < 0.05) were the sole negative prognostic factors identified in our study by multivariate analysis (p < 0.05). Overall, our study provides genetic insights into various MDS/MPN subtypes, which may aid in diagnosis and clinical decision-making for patients with MDS/MPN. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

35. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Koller, Paul, Tsai, Ni‐Chun, Yang, Dongyun, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Spielberger, Ricardo, Sahebi, Firoozeh, Al Malki, Monzr M., Cai, Ji‐Lian, Sandhu, Karamjeet S., Mansour, Joshua, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, and Marcucci, Guido

Published
2024
Full Text
View/download PDF

36. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer.

Author

Pourhassan, Hoda, Zhang, Jianying, Tinajero, Jose, Pullarkat, Vinod, Agrawal, Vaibhav, Koller, Paul, Al Malki, Monzr, Aribi, Ahmed, Salhotra, Amandeep, Sandhu, Karamjeet, Ali, Haris, Stein, Anthony, Marcucci, Guido, Forman, Stephen, and Aldoss, Ibrahim

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, BREAST cancer, CARCINOGENS, PHILADELPHIA chromosome
Abstract

Summary: Therapy‐related acute lymphoblastic leukaemia (tr‐ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr‐ALL, likely due to high prevalence and excellent curable rate for non‐metastatic breast cancer as well as the frequent use of carcinogenic agents as part of adjuvant therapy. Here, we reviewed 37 women with diagnosis of ALL following breast cancer treatment with focus on cytogenetic categorization. Philadelphia chromosome positivity (Ph+), KMT2A alterations and other cytogenetic change groups were observed in 32%, 22% and 46% of patients respectively. Median overall survival (OS) and relapse‐free survival (RFS) were 19.4 and 12.9 months, overall while both OS and RFS were superior in tr‐ALL with Ph+ disease compared to KMT2Ar and other cytogenetics respectively. Seventeen (45.9%) patients underwent consolidative allogeneic haematopoietic cell transplantation (alloHCT) in CR1 out of which 4 (24%) relapsed following transplant. Both OS and RFS were superior in the KMT2Ar cytogenetics group following alloHCT. Ph chromosome represents the largest genetic entity of tr‐ALL following breast cancer therapy, and it may be associated with superior survival outcomes while KMT2Ar may be associated with poorer outcomes that can perhaps be mitigated by alloHSCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

38. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

Author

Mei, Matthew, Tsai, Ni-Chun, Mokhtari, Sally, Al Malki, Monzr M., Ali, Haris, Salhotra, Amandeep, Sandhu, Karamjeet, Khaled, Samer, Smith, Eileen, Snyder, David, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Stein, Anthony, Aldoss, Ibrahim, and Nakamura, Ryotaro

Published
2020
Full Text
View/download PDF

39. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Salhotra, Amandeep, Yang, Dongyun, Mokhtari, Sally, Malki, Monzr M. Al, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Mei, Matthew, Budde, Elizabeth, Snyder, David, Cao, Thai, Spielberger, Ricardo, Marcucci, Guido, Pullarkat, Vinod, Forman, Stephen J., Nakamura, Ryotaro, Stein, Anthony, and Aldoss, Ibrahim

Published
2020
Full Text
View/download PDF

41. Survival following allogeneic transplant in patients with myelofibrosis

Author

Gowin, Krisstina, Ballen, Karen, Ahn, Kwang Woo, Hu, Zhen-Huan, Ali, Haris, Arcasoy, Murat O., Devlin, Rebecca, Coakley, Maria, Gerds, Aaron T., Green, Michael, Gupta, Vikas, Hobbs, Gabriela, Jain, Tania, Kandarpa, Malathi, Komrokji, Rami, Kuykendall, Andrew T., Luber, Kierstin, Masarova, Lucia, Michaelis, Laura C., Patches, Sarah, Pariser, Ashley C., Rampal, Raajit, Stein, Brady, Talpaz, Moshe, Verstovsek, Srdan, Wadleigh, Martha, Agrawal, Vaibhav, Aljurf, Mahmoud, Angel Diaz, Miguel, Avalos, Belinda R., Bacher, Ulrike, Bashey, Asad, Beitinjaneh, Amer M., Cerny, Jan, Chhabra, Saurabh, Copelan, Edward, Cutler, Corey S., DeFilipp, Zachariah, Gadalla, Shahinaz M., Ganguly, Siddhartha, Grunwald, Michael R., Hashmi, Shahrukh K., Kharfan-Dabaja, Mohamed A., Kindwall-Keller, Tamila, Kröger, Nicolaus, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., Marks, David I., Nathan, Sunita, Nishihori, Taiga, Olsson, Richard F., Pawarode, Attaphol, Rowe, Jacob M., Savani, Bipin N., Savoie, Mary Lynn, Seo, Sachiko, Solh, Melhem, Tamari, Roni, Verdonck, Leo F., Yared, Jean A., Alyea, Edwin, Popat, Uday, Sobecks, Ronald, Scott, Bart L., Nakamura, Ryotaro, Mesa, Ruben, and Saber, Wael

Published
2020
Full Text
View/download PDF

42. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

Author

Salhotra, Amandeep, Hui, Susanta, Yang, Dongyun, Mokhtari, Sally, Mei, Matthew, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Dandapani, Savita, Peng, Kelly, Teh, Jennifer Berano, Murata-Collins, Joyce, Budde, Elizabeth, Dadwal, Sanjeet, Pullarkat, Vinod, Snyder, David, Spielberger, Ricardo, Wong, Jeffry, Armenian, Saro, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Stein, Anthony

Published
2020
Full Text
View/download PDF

44. Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Author

Salhotra, Amandeep, primary, Yang, Dongyun, additional, Mokhtari, Sally, additional, Modi, Badri, additional, Al Malki, Monzr M., additional, Ali, Haris, additional, Amanam, Idoroenyi, additional, Karras, Nicole, additional, Sandhu, Karamjeet S., additional, Aribi, Ahmed, additional, Otoukesh, Salman, additional, Artz, Andrew S., additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Smith, Eileen, additional, Zeng, Defu, additional, Rosen, Steven, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

45. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience

Author

Samara, Yazeed, primary, Yao, Janny, additional, Tsai, Ni-Chun, additional, Mokhtari, Sally, additional, Aldoss, Ibrahim, additional, Ali, Haris, additional, Sandhu, Karamjeet S., additional, Salhotra, Amandeep, additional, Stein, Anthony S., additional, Arslan, Shukaib, additional, Aribi, Ahmed, additional, Borogovac, Azra, additional, Malki, Monzr M. Al, additional, Blackmon, Amanda, additional, Otoukesh, Salman, additional, Amanam, Idoroenyi, additional, Artz, Andrew S., additional, Curtin, Peter, additional, Pourhassan, Hoda, additional, Koller, Paul, additional, Ball, Brian, additional, Agrawal, Vaibhav, additional, Spielberger, Ricardo, additional, Becker, Pamela S., additional, Stewart, F. Marc, additional, Smith, Eileen, additional, Marcucci, Guido, additional, Forman, Stephen J., additional, Pullarkat, Vinod, additional, and Nakamura, Ryotaro, additional

Published
2024
Full Text
View/download PDF

46. Phase 2 study of add-on parsaclisib in myelofibrosis patients with suboptimal response to ruxolitinib: Final results

Author

Yacoub, Abdulraheem, primary, Borate, Uma, additional, Rampal, Raajit K., additional, Ali, Haris, additional, Wang, Eunice S., additional, Gerds, Aaron T., additional, Hobbs, Gabriela Soriano, additional, Kremyanskaya, Marina, additional, Winton, Elliott F., additional, O'Connell, Casey, additional, Goel, Swati, additional, Oh, Stephen T., additional, Schiller, Gary J., additional, McCloskey, James, additional, Palmer, Jeanne M., additional, Holmes, Houston, additional, Hager, Steven, additional, Assad, Albert, additional, Erickson-Viitanen, Susan, additional, Zhou, Feng, additional, and Daver, Naval G., additional

Published
2024
Full Text
View/download PDF

48. Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis

Author

Yao, Janny M., Otoukesh, Salman, Kim, Hanna, Yang, Dongyun, Mokhtari, Sally, Samara, Yazeed, Blackmon, Amanda, Arslan, Shukaib, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Ball, Brian, Koller, Paul, Salhotra, Amandeep, Becker, Pamela, Curtin, Peter, Artz, Andrew, Aldoss, Ibrahim, Ali, Haris, Stewart, Forrest, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2023
Full Text
View/download PDF

49. Investigating power, interdependence and struggle in the employment relationship : a psychological contract perspective

Author

Ali, Haris

Subjects
658.3, H Social Sciences (General)
Abstract

This thesis explores the implications of power in relation to the psychological contract. The majority of the psychological contract literature, because of its underpinning assumptions of mutuality and reciprocity, largely downplays the dynamics of power in the employment relationship. The key objective of the current study therefore is to make further empirical and theoretical developments in relation to the psychological contract by exploring these power dynamics in the relationship between employees and employer. Concerning power, the complex interdependencies and the associated workplace struggles characterizing the employment relationship between employees and the different representatives of the organization are investigated. From an empirical perspective, the research contributes in a twofold manner as the results not only highlight the complex interdependencies and the workplace struggles in the employment relationship but also offer new knowledge about work and management in Pakistan. This context of employment relations based on underlying power dynamics that are embedded into the complex and interdependent relationships between employees and organizational representatives is globally significant in terms of workplace research, yet generally neglected in the relevant studies. The current study has a qualitative orientation and follows a critical realist research philosophy. Using data collected from 43 interviewees in three call centre organizations, the research additionally makes a theoretical contribution to the psychological contract from the perspectives of mutuality, reciprocity and agency. The results illustrate that, in comparison to mutuality and reciprocity, interdependence and negotiation play a critical role in the psychological contracts of employees. Largely acknowledging the implications of power dynamics, these concepts highlight that employees, based on their perceptions of interdependence (rather than mutuality) in the employment relationships, tend to focus primarily on negotiation (rather than reciprocation) in their psychological contracts with employers. Concerning agency, different classifications of human agents are highlighted (i.e. primary agents, secondary agents, multiple agents, incumbent agents). The current research extends the concept of agency beyond the boundary of human agents into the domain of the electronic agents of the organization. The results highlight that it is not only the perceived capability to reward or punish but also the perceived tendency to actively use that capability which significantly influences employees’ assumptions to consider particular organizational members as the agents of the organization. From the viewpoint of relational interdependence in the employment relationship, the efforts made by employees to decrease their dependence on employers and increase the employer’s dependence on them are illustrated. The research findings demonstrate that these efforts are largely motivated by the employees’ objective of promoting their bargaining power in employment relationship.

Published
2015

50. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

Author

Gupta, Rohan, Jamal, Faizi, Yang, Dongyun, Chendri, Chendri, Aldoss, Ibrahim, Malki, Monzr Al, Mei, Matthew, Salhotra, Amandeep, Dobrin, Surime, Tran, Michael, Venkataraman, K., Palmer, Joycelynne, Stein, Anthony S., Sandhu, Karamjeet, Khaled, Samer, Aribi, Ahmed, Marcucci, Guido, Forman, Stephen J., Snyder, David, Nakamura, Ryotaro, Ali, Haris, and Pullarkat, Vinod

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results